The Surprising FDA View That Sent Moderna Stock Flying
Moderna stock prices increased following positive feedback from the FDA regarding the company's mRNA influenza vaccine candidate.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The FDA has released a review appearing to align with Moderna's development of an mRNA-based influenza vaccine. This development coincides with reports that the technology expands B cell response breadth and provides protection against a diverse range of influenza strains.
Coverage from Fierce Biotech, BioSpace, and Investor's Business Daily emphasizes the current alignment between regulators and the company. Nature and Medical Xpress provide the underlying scientific context regarding the vaccine's ability to trigger broader human immune responses.
Market participants are monitoring the upcoming advisory committee meeting. Coverage does not yet specify the exact date of the adcomm grilling or the specific metrics of the stock price movement.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 47d ago.
Quick answers
Why did Moderna stock rise?
Investor's Business Daily reports the increase followed a favorable review from the FDA concerning the company's mRNA flu vaccine.
What does the science say about the vaccine?
According to Nature and Medical Xpress, the vaccine has shown potential to expand the breadth of human B cell responses and offer protection against diverse influenza strains.
What is the next step for the vaccine?
Fierce Biotech and BioSpace indicate that an advisory committee review is the next significant event.
Coverage (10)
- MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval Concerns Yahoo Finance · 47d ago
- Quick takes: Moderna mRNA flu vaccine review, NIH award for genital herpes vaccine, malaria monoclonal antibody trial CIDRAP · 47d ago
- FDA appears open to Moderna’s flu vaccine ahead of adcomm statnews.com · 47d ago
- Moderna flu shot data may support use in older adults, US FDA staff says Reuters · 47d ago
- Why Is Moderna (MRNA) Stock Soaring Today Yahoo Finance · 47d ago
- Amenable FDA review bodes well for Moderna's mRNA flu shot ahead of adcomm grilling Fierce Biotech · 47d ago
- mRNA-based influenza vaccine expands the B cell response breadth in humans Nature · 47d ago
- mRNA flu vaccine offers immune protection against diverse strains Medical Xpress · 47d ago
- FDA, Moderna appear aligned on mRNA flu shot heading into adcomm BioSpace · 47d ago
- The Surprising FDA View That Sent Moderna Stock Flying Investor's Business Daily · 47d ago
Topics
Related trends
FDA Panel Backs 6 Peptides for Compounding
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Nearly 12 million bottles of Rohto eye drops over sterility concerns, FDA announces
The FDA announces a recall of nearly 12 million bottles of Rohto eye drops due to sterility concerns.
Fruit sold at Publix sickens multiple people in 8 states
12 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
New, more efficient pill to lower cholesterol
FDA approves first oral PCSK9 inhibitor for adults with high cholesterol, changing treatment options.
FDA Panel Votes In Favor of Replimune’s Melanoma Treatment
Replimune shares surge following a favorable FDA advisory panel vote for its melanoma treatment.